Vedolizumab and Anti-Vedolizumab Antibody, DoseASSURE™ VDZ
Also known as: Anti-integrin drug, Biological monitoring, DoseASSURE, Entyvio, Immunogenicity testing
Use
Provides serum concentrations of vedolizumab and anti-vedolizumab antibodies in order to optimize treatment and facilitate clinical decision-making.
Special Instructions
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. To avoid delays in turnaround time when requesting multiple tests on frozen samples, submit separate frozen specimens for each test. Patients are advised to stop biotin consumption at least 72 hours prior to sample collection to prevent assay interference.
Limitations
The drug half-life should be considered when interpreting concentrations in non-trough collections. High serum biotin concentrations can interfere with this assay, necessitating a stoppage of biotin intake 72 hours before sample collection. The presence of vedolizumab does not affect the anti-vedolizumab antibody measurement as all positive results are verified by a confirmatory test.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 90794-9
- 86898-4
- 86899-2
Result Turnaround Time
8-15 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
1 mL
Container
Serum-gel tube, red-top tube, green top (heparin) tube, or lavender top (EDTA) tube
Collection Instructions
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum/plasma in a plastic transport tube.
Patient Preparation
Patients should stop biotin consumption at least 72 hours prior to sample collection.
Storage Instructions
Refrigerate or freeze
Causes for Rejection
Gross hemolysis; gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |